Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
21 Results for "
CRISPR
" in MedChemExpress (MCE) Product Catalog:
Products (21)
21 Results for "CRISPR" in MCE Product Catalog:
Cat. No.: HY-P5307
Synonyms: INF7-A5K-TAT
Target:
Research Areas:
Target:
Research Areas:
PolQi1 is a selective inhibitor targeting the Polθ domain of DNA polymerase. PolQi1 inhibits the Polθ-mediated microhomology end joining (TMEJ/alt-EJ) pathway, reducing insertion/deletion (Indels) and imprecise editing events during DNA repair. PolQi1 can enhance the efficiency and accuracy of homology-directed repair (HDR) or Prime editing, and reduce off-target effects; and in combination with DNA-PK inhibitor AZD-7648 (HY-111783), exert efficient genome editing capabilities with dual pathway regulation. PolQi1 can be mainly used in gene editing research (such as CRISPR-Cas9 or Prime editing system optimization) to improve the precision editing efficiency of difficult-to-edit cells (such as primary hepatocytes and mouse embryos) .
Cat. No.: HY-159579
CAS No.: 3055592-99-6
Target:
Research Areas:
CW-3308 is an orally active BRD9 PROTAC degrader with an DC50 of 92 nM. CW-3308 forms a ternary complex with BRD9 and cereblon to mediate BRD9 degradation. CW-3308 inhibits the viability of synovial sarcoma and rhabdoid tumor cells. CW-3308 reduces BRD9 protein levels in xenograft tumor tissues and suppresses tumor growth in xenograft models. CW-3308 can be used for the research of synovial sarcoma and rhabdoid tumors .
Cat. No.: HY-159190
CAS No.: 2409140-12-9
Target:
Research Areas:
HRX-0233 is an orally potent MAP2K4 inhibitor. HRX-0233 inhibits the MAP2K4-JNK-JUN signaling pathway, blocks the feedback activation of receptor tyrosine kinases, and sustains the inhibitory effect on KRAS signaling. HRX-0233 exerts synergistic inhibition on the mTORC1 and MAPK pathways. When combined with Ipatasertib (HY-15186) or Sotorasib (HY-114277), it produces synergistic antiproliferative, pro-apoptotic (apoptosis) and antitumor effects, and shows good tolerability in mouse models. HRX-0233 can be used in CRISPR knockout screens to identify vulnerability-related genes. HRX-0233 is applicable to research related to prostate cancer, non-small cell lung cancer and colorectal cancer .
Cat. No.: HY-159709
CAS No.: 2765519-47-7
Target:
Research Areas:
VL-422 is an ionizable cationic lipid. VL-422 delivers CRISPR complementary single-guide RNA (sgRNA) and Cas9 mRNA to enable in vitro and in vivo gene editing. LNPs containing VL-422 loaded with Cas9 mRNA and sgRNA targeting the ANGPTL3 gene induce the deletion of premature stop codons within the ANGPTL3 gene in the liver of cynomolgus monkeys. Loss-of-function of ANGPTL3 leads to decreased levels of LDL, HDL and cholesterol in plasma. The VL-422 delivery system can be used for the research of gene editing strategies targeting lipid metabolism diseases .
Cat. No.: HY-P5307A
Synonyms: INF7-A5K-TAT acetate
Target:
Research Areas:
Cat. No.: HY-P10999
Synonyms: P55
Research Areas:
Cat. No.: HY-174499
Cas9 Nickase D10A mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9) that contains a D10A amino acid substitution. This mRNA also contains a C-terminal nuclear localization signal followed by a HA tag.Cas9 functions as part of the CRISPR (clustered regularly interspaced short palindromic repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform the DNA cleavage. While wild-type Cas9 creates a double-stranded break at the target site, Cas9 nickase creates a single-stranded break. This favors homology-directed repair and decreases the occurrence of non-homologous end joining.
Cat. No.: HY-157426
CAS No.: 3093737-33-5
Target:
Research Areas:
PROTAC BRD4 Degrader-50 is a BRD4 PROTAC degrader with a DC50 of 11.4 nM (HEK293). PROTAC BRD4 Degrader-50 induces BRD4 degradation via the proteasome and CRBN. PROTAC BRD4 Degrader-50 is applicable to cancer research .
Cat. No.: HY-171953
CAS No.: 3097638-13-3
THP1 Lipid is an ionizable lipidoid. THP1 Lipid can be used to synthesize lipid nanoparticles (LNPs) for delivering mRNA to muscles with minimal toxicity and editing genes in specific liver tissues in tdTomato transgenic mice model. THP1 Lipid can be used for vaccine delivery and CRISPR/Cas9-mediated gene editing research .
Cat. No.: HY-171904
BCP-NC2-C12 is an ionizable cationic lipid. BCP-NC2-C12 can be used to generate lipid nanoparticles (LNPs) for in vivo delivery of mRNA. BCP-NC2-C12 LNPs mediated an approximately 90% reduction in PCSK9 serum protein levels via CRISPR/Cas9 gene knockout .
Cat. No.: HY-165603
CAS No.: 3006860-57-4
Research Areas:
Si5-N14 is a key component of siloxane-incorporated lipid nanoparticles (SiLNP), possessing pro-vascular repair and anti-tumor activities. In the transgenic GFP mouse model, Si5-N14 can mediate CRISPR-Cas9 editing. In the Lewis lung carcinoma (LLC) tumor-bearing mouse model, Si5-N14 can knock out the expression of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) to exert an anti-tumor effect. In a mouse model of lung injury induced by viral infection, the delivery of Fibroblast Growth Factor-2 (FGF-2) mRNA via Si5-N14 can promote vascular repair, increase blood oxygen levels, and improve lung function. Si5-N14 shows promise for research in the fields of oncology, pneumonia, and cardiovascular diseases .
Cat. No.: HY-185504
Nexiguran is one component of Nexiguran ziclumeran and also an sgRNA targeting the human TTR gene. Nexiguran ziclumeran (NTLA-2001) is a CRISPR gene-editing therapy that targets hepatic TTR, and it can also be used for research on transthyretin amyloidosis .
Cat. No.: HY-W1130456
CAS No.: 2855180-86-6
Target:
Research Areas:
Lipid TD5 is an ionizable cationic lipid with a pKa value of 7.3. Lipid TD5 can be used to prepare lipid nanoparticles (LNPs), which efficiently deliver mRNA and the CRISPR/Cas9 system to the central nervous system and enable their expression .
Cat. No.: HY-185702
CAS No.: 3069451-89-1
Target:
Research Areas:
DMT-dU (Crotonic hexanediamine 3-(benzoylthio) propanoic)-CE phosphoramidite is a phosphoramidite reagent used to synthesize chemically modified guide RNAs for forming CRISPR-Cas RNP conjugates with Cas proteins. DMT-dU (Crotonic hexanediamine 3-(benzoylthio) propanoic)-CE phosphoramidite can be applied in research on antiviral agents, cancer, neurodegenerative diseases and genetic diseases .
Cat. No.: HY-P10999A
Synonyms: P55 acetate
Research Areas:
Cat. No.: HY-L244
756 compounds
In this era of rapid advancement in gene-editing technology, the CRISPR-Cas system, with its powerful programmability, is leading a transformation in life sciences research. It enables efficient and precise targeted modification of an organism's genome, providing a robust tool for studying gene function, treating genetic diseases, and improving crop varieties. However, bottlenecks such as insufficient editing efficiency, low homologous directed repair efficiency, and potential off-target risks remain major challenges in achieving precise genetic modifications and developing gene therapies.
To overcome these limitations, the MCE High-Efficiency Gene Editing Compound Library systematically includes 756 small molecules that are known or have the potential to enhance gene-editing efficiency. These compounds work by targeting and modulating the DNA damage repair network, mechanistically inhibiting non-homologous end joining, promoting homologous directed repair, or regulating chromatin states and cellular responses, thereby significantly optimizing editing outcomes. This library is suitable for developing "CRISPR-small molecule" combination therapy strategies, improving gene-editing efficiency, and providing a powerful tool for in-depth research into the mechanisms of DNA damage repair in gene editing.
Cat. No.: HY-185053
Cas12a mRNA is the messenger RNA encoding Cas12a. Cas12a mRNA undergoes translation-dependent degradation triggered by the anti-CRISPR protein AcrVA2, which recognizes and binds to the N-terminal polypeptide of Cas12a. AcrVA2-triggered Cas12a mRNA degradation is independent of promoter or codon sequences, requiring only the first 100 amino acids of the Cas12a polypeptide. The down-regulation of Cas12a mRNA by AcrVA2 inhibits the biosynthesis of Cas12a .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
